Scarica l'app Stockscreener
5.54
10.06%
-0.62
Dopo l'orario di chiusura:
5.59
0.05
+0.90%
Precedente Chiudi:
$6.16
Aprire:
$6.1
Volume 24 ore:
1.64M
Relative Volume:
1.05
Capitalizzazione di mercato:
$230.30M
Reddito:
$317.00K
Utile/perdita netta:
$-53.47M
Rapporto P/E:
-2.9312
EPS:
-1.89
Flusso di cassa netto:
$-49.31M
1 W Prestazione:
-11.22%
1M Prestazione:
-33.33%
6M Prestazione:
+343.20%
1 anno Prestazione:
+149.55%
Intervallo 1D:
$5.52
$6.27
Intervallo di 1 settimana:
$5.52
$6.42
Portata 52W:
$1.10
$10.08
Immuneering Corp Stock (IMRX) Company Profile
Nome
Immuneering Corp
Settore
Industria
Telefono
617-500-8080
Indirizzo
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Confronta IMRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
5.54 | 376.90M | 317.00K | -53.47M | -49.31M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-13 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2024-03-15 | Downgrade | Jefferies | Buy → Hold |
| 2024-03-15 | Reiterato | Needham | Buy |
| 2024-03-15 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-12-01 | Iniziato | Needham | Buy |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-04-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-04-19 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-03-30 | Iniziato | Mizuho | Neutral |
| 2023-02-03 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2022-07-08 | Iniziato | Chardan Capital Markets | Buy |
| 2022-04-01 | Iniziato | Oppenheimer | Outperform |
| 2022-01-07 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Immuneering Corp Borsa (IMRX) Ultime notizie
Immuneering’s Cancer Drug Bets Deliver A Market-Beating Year - Finimize
Evaluating Immuneering Corporation with trendline analysisQuarterly Market Review & Real-Time Stock Price Movement Reports - newser.com
Immuneering Corporation stock outlook for YEARMarket Activity Summary & Accurate Entry/Exit Alerts - newser.com
How Immuneering Corporation stock valuations compare to rivalsJuly 2025 Action & Daily Profit Focused Stock Screening - newser.com
Is Immuneering Corporation stock ready for a breakoutJuly 2025 Action & AI Enhanced Trading Signals - newser.com
Will Immuneering Corporation stock outperform value stocksJuly 2025 Rallies & Stock Timing and Entry Methods - newser.com
Forecasting Immuneering Corporation price range with options dataJuly 2025 Fed Impact & Community Consensus Picks - newser.com
Key metrics from Immuneering Corporation’s quarterly data2025 Market WrapUp & Low Drawdown Investment Ideas - newser.com
Is it too late to sell Immuneering CorporationJuly 2025 Market Mood & Safe Swing Trade Setups - newser.com
Why Immuneering Corporation stock is in analyst buy zoneJuly 2025 Retail & Risk Adjusted Buy/Sell Alerts - newser.com
Can Immuneering Corporation stock sustain market leadershipLong Setup & Community Trade Idea Sharing - newser.com
Weiss Ratings Reiterates Sell (E+) Rating for Immuneering (NASDAQ:IMRX) - MarketBeat
Insider Stock Purchases: October 07, 2025 - Quiver Quantitative
Insider Buying: Immuneering (NASDAQ:IMRX) Director Purchases 7,500 Shares of Stock - MarketBeat
Will Immuneering Corporation stock outperform Nasdaq indexJuly 2025 Setups & Verified Momentum Stock Watchlist - newser.com
Analyzing recovery setups for Immuneering Corporation investorsMarket Activity Summary & Consistent Profit Focused Trading Strategies - newser.com
What to expect from Immuneering Corporation in the next 30 daysEarnings Performance Report & Free Community Supported Trade Ideas - newser.com
Will Immuneering Corporation stock benefit from commodity prices2025 Retail Activity & Weekly High Return Stock Opportunities - newser.com
Two new option listings and three option delistings on October 2nd - TipRanks
Immuneering Corporation (NASDAQ:IMRX) Receives $17.75 Consensus PT from Analysts - Defense World
Insider Stock Purchases: October 01, 2025 - Quiver Quantitative
Feinberg Peter buys Immuneering Corp (IMRX) shares for $52,730 - Investing.com India
Positive Trial Data Supports 43% Upside for Immuneering Corporation (IMRX) - Insider Monkey
Peter Feinberg Acquires 5,000 Shares of Immuneering (NASDAQ:IMRX) Stock - MarketBeat
Will Product Innovation Drive Rajasthan Gases Limited Stock in YEARInstitutional Buying Trends & Create Your Free Watchlist Instantly - earlytimes.in
11 Best Fast Money Stocks to Buy Now - Insider Monkey
Transcript : Immuneering CorporationSpecial Call - MarketScreener
Identifying reversal signals in Immuneering Corporation2025 Analyst Calls & Risk Managed Investment Signals - newser.com
Immuneering Corporation (NASDAQ:IMRX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Immuneering (NASDAQ:IMRX) Price Target Raised to $20.00 at Chardan Capital - Defense World
Immuneering Corporation's (NASDAQ:IMRX) last week's 13% decline must have disappointed individual investors who have a significant stake - Sahm
Immuneering to host call on pancreatic cancer treatment data By Investing.com - Investing.com Nigeria
Immuneering To Discuss Recently Announced Overall Survival Data From Phase 2A Clinical Trial Of Atebimetinib + Mgnp In First-Line Pancreatic Cancer Patients On September 29 - TradingView
MBX, uniQure among biotechs raising nine-figure sums: Public Equity Report - biocentury.com
Immuneering to host call on pancreatic cancer treatment data - Investing.com
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025 - The Manila Times
First-Line Pancreatic Cancer Trial Update: Immuneering to Present Survival Data for Atebimetinib + mGnP - Stock Titan
Immuneering (NASDAQ:IMRX) Price Target Raised to $30.00 at Oppenheimer - Defense World
Immuneering Corp Azioni (IMRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Immuneering Corp Azioni (IMRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Morales Mallory | Chief Accounting Officer |
Oct 01 '25 |
Buy |
6.39 |
300 |
1,917 |
27,533 |
| Neufeld Leah R | CHIEF PEOPLE OFFICER |
Oct 01 '25 |
Buy |
6.38 |
800 |
5,103 |
23,344 |
| Bookman Michael | CHIEF LEGAL OFFICER, SECRETARY |
Oct 01 '25 |
Buy |
6.83 |
1,020 |
6,966 |
4,870 |
| Feinberg Peter | Director |
Sep 30 '25 |
Buy |
7.03 |
7,500 |
52,730 |
149,266 |
| Feinberg Peter | Director |
Sep 29 '25 |
Buy |
7.18 |
5,000 |
35,900 |
141,766 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):